WhichTrial Monthly Report · Issue 6

The US Clinical Trial Recruiting Pipeline

September 2026 → October 2026. One month of movement, and a continuity check on the drugs we've been tracking.

Published October 30, 2026 · Data through 2026-10 · By WhichTrial

The numbers at a glance

12,359

drugs in active recruiting trials (October 2026)

10,834

of 30,933 recruiting trials have a US site

383

drugs exited recruiting since September

515

drugs entered recruiting since September

One month of change. The recruiting pipeline grew by 132 drugs on net. 362 drugs picked up additional recruiting trials, 214 lost ground but kept at least one open study, and 11,268 held flat. It was a quiet month. The largest moves in either direction were nine trials: Pembrolizumab and Fludarabine up nine, Atezolizumab down nine. Only 12 drugs moved by five or more. The gainers list is mostly chemotherapy and immunotherapy backbones (carboplatin, bevacizumab, cyclophosphamide, oxaliplatin, cisplatin) rising together, which reads as new combination trials opening rather than any single drug breaking out. The news is in the continuity check below: Issue 5's two-sponsor read on Pumitamig broke, and its call on Elecoglipron is on hold.

A note on scope. We track every trial recruiting worldwide for these 17 conditions, but we only record trial sites located in the United States. Of the 30,933 trials recruiting for these conditions right now, 10,834 have at least one US site you could enroll at. The remaining 20,099 are running entirely outside the US. Drug-level counts throughout this report are worldwide unless stated otherwise; where a drug's US footprint differs sharply from its worldwide one, we say so.

Top gainers

Drugs that added the most recruiting trials between September and October. Over a single month the moves at the top of this list are small by nature, a few trials each, and this month they are mostly chemotherapy and immunotherapy backbones. Pembrolizumab, highlighted below, is one of the drugs in this month's continuity check.

DrugSepOctΔ trialsSponsors
Pembrolizumab418427+9235
Fludarabine195204+989
carboplatin311319+8169
Bevacizumab207215+8134
Cyclophosphamide340347+7149
Dexamethasone163169+6106
Oxaliplatin150156+696
Trastuzumab Deruxtecan5359+637
Capecitabine164169+5101
Cetuximab8085+558
Fluorouracil5560+540
Cisplatin253257+4157
Docetaxel145149+4106
Tislelizumab9195+464
Irinotecan7680+471

Top losers

Drugs that lost the most recruiting trials but still have at least one study open. A drop here means trials have moved out of the recruiting phase. They either completed enrollment, were terminated, or moved to active-not-recruiting status. Atezolizumab, highlighted below, had the largest drop and is covered in the continuity check.

DrugSepOctΔ trialsSponsors
Atezolizumab10293-975
Abemaciclib6157-440
Acalabrutinib2925-421
Temozolomide7875-361
Palbociclib3734-328
Ribociclib3229-322
Trametinib2320-319
Durvalumab109107-278
Vincristine7068-243
Olaparib5351-240
Obinutuzumab:5149-231
enfortumab vedotin3331-224
Tremelimumab2624-221
Apatinib2321-216
Regorafenib2119-217

Spotlight · Continuity check

Pumitamig picks up outside sponsors, Elecoglipron pauses

Issue 5 ended with one call. If Elecoglipron's trial count kept climbing while its sponsor count stayed at one, that would be a single-company registrational program running ahead of its visibility. This month it did neither. It sits at eight recruiting trials, all phase 3, all sponsored by AstraZeneca, seven with a US site, on ten conditions, exactly where it was in September. The climb from one trial in June to eight paused. It did not reverse, and nothing about the program's shape changed, so the call carries forward to Issue 7.

Pumitamig is where a call broke. For six snapshots it had exactly two sponsors, Bristol-Myers Squibb and BioNTech, and Issues 4 and 5 read that as two companies pushing one asset rather than broad adoption. This month it went from 23 trials to 26 and from two sponsors to four. The newcomers are small: M.D. Anderson Cancer Center and Boehringer Ingelheim lead one trial each, while BMS runs 14 and BioNTech 10. Two sponsors with one trial each is not broad adoption either, but it is the first time anyone outside the original pair has led a Pumitamig study. Twenty-three of the 26 have a US site.

The month's largest drop was Atezolizumab, down nine trials to 93, with sponsors down 81 to 75 and conditions 255 to 243. It is a steady slide rather than a one-month event: 111 trials in March, then 107, 106, 104, 102 and now 93. The CDK4/6 class drifted the same way on a smaller scale, with Abemaciclib down four and Palbociclib and Ribociclib down three each.

Pembrolizumab kept the gains Issue 5 flagged, rising for a second month on every count: trials 418 to 427, sponsors 231 to 235, conditions 807 to 823. Nivolumab went the other way: trials flat at 160, sponsors down two, and conditions down 39, from 512 to 473, the largest condition drop of any drug in the snapshot. The gap between the two PD-1 backbones is widening again.

Ivonescimab, which did not move on any count last month, picked back up: 36 to 40 trials, 23 to 27 sponsors, 73 to 78 conditions. Its sponsor base keeps widening along with its trials, the opposite of the Pumitamig pattern. A separately named entry, “Ivonescimab Combined With Chemotherapy”, adds two more trials that are not in these counts.

In the GLP-1 class, Semaglutide rose 27 to 31 trials and recovered two sponsors, while Tirzepatide added one, 36 to 37. The gap between them narrowed from nine trials to six. Sacituzumab tirumotecan held at 24 trials and widened to 37 conditions, and BL-B01D1 slipped one to 31 with still just one US-sited trial.

The calls for Issue 7. Elecoglipron carries over: one more month flat would make eight trials look like the program's size rather than a pause. And if Atezolizumab falls again while Pembrolizumab keeps adding, the checkpoint-inhibitor class is consolidating around Pembrolizumab rather than shrinking as a whole.

DrugTrials (Aug → Sep → Oct)With US site (Oct)Sponsors (Sep → Oct)
ElecoglipronIssue 5's call; still one sponsor5 → 8 → 8 (0)7 of 81 → 1
PumitamigIssue 4 spotlight; now 4 sponsors21 → 23 → 26 (+3)23 of 262 → 4
Atezolizumabthis month's largest drop104 → 102 → 93 (-9)66 of 9381 → 75
Pembrolizumabrecurring PD-1 leader; in this month's top gainers413 → 418 → 427 (+9)331 of 427231 → 235
Nivolumabrecurring PD-1 leader159 → 161 → 160 (-1)118 of 16096 → 94
Ivonescimabflat in Issue 5; moving again36 → 36 → 40 (+4)20 of 4023 → 27
Semaglutiderecurring GLP-1 class leader27 → 27 → 31 (+4)15 of 3120 → 22
Tirzepatiderecurring GLP-1 class leader36 → 36 → 37 (+1)23 of 3733 → 33
Sacituzumab tirumotecanTROP2 ADC watch22 → 24 → 24 (0)19 of 246 → 6
BL-B01D1worldwide mover, 1 US-sited trial31 → 32 → 31 (-1)1 of 313 → 3

Drugs that left recruiting

383 drugs that had at least one recruiting trial in September no longer do in October. Over a one-month window these are typically long-tail compounds with one or two trials that wrapped enrollment.

New entrants

515 drugs began recruiting between September and October that hadn't previously appeared in our snapshot. As usual, most are early-phase, single-sponsor studies, the first signals of new programs.

Who is actually running the trials

Since Issue 4 we have tracked which organization leads each trial. The ranking below is the current picture.

2,463 organizations are running the 10,834 trials recruiting at US sites. The 10 largest run 19% of everything open, while 1,655 organizations, 67% of all sponsors, are running exactly one trial each.

The percentage below is how much of an organization's work sits in its single biggest condition, which separates the specialists from the generalists. Conditions overlap, so a trial can count toward more than one and the percentages do not sum to 100 across a row.

OrganizationUS trials
M.D. Anderson Cancer Center419
Memorial Sloan Kettering Cancer Center293
Mayo Clinic292
National Cancer Institute (NCI)279
Massachusetts General Hospital164
City of Hope Medical Center145
AstraZeneca118
Washington University School of Medicine116
University of California, San Francisco105
Stanford University102

These are lead sponsors only. ClinicalTrials.gov records one lead sponsor per trial and does not let us count collaborators, so every figure here understates how involved an organization really is. The full rankings cover the top 25 and how the whole field is distributed.

What changed since September

Counted in US-sited recruiting trials, 2,463 organizations have at least one, against 2,472 last month. 198 ran more US trials than in September and 191 ran fewer, while 77 appear for the first time and 86 dropped to none. One of those entries and one of those exits is the same organization: the registry renamed University of Illinois at Chicago (44 US trials) to University of Illinois Chicago (46), so we leave it out of the lists below. Pharma led the risers for a second month. GlaxoSmithKline added eight US trials, after six last month, and Pfizer and Novo Nordisk five each. Novartis was the only pharma company among the biggest fallers, down three.

Biggest risers

OrganizationUS trials (Sep → Oct)
GlaxoSmithKline39 → 47 (+8)
The Foundation for Orthopaedics and Regenerative Medicine0 → 8 (+8)
Massachusetts General Hospital159 → 164 (+5)
City of Hope Medical Center140 → 145 (+5)
Stanford University97 → 102 (+5)
Duke University80 → 85 (+5)
Pfizer37 → 42 (+5)
Vanderbilt-Ingram Cancer Center25 → 30 (+5)
Novo Nordisk A/S15 → 20 (+5)
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)9 → 14 (+5)

Biggest fallers

OrganizationUS trials (Sep → Oct)
University of Florida64 → 60 (-4)
Tulane University12 → 8 (-4)
UNC Lineberger Comprehensive Cancer Center71 → 68 (-3)
Novartis Pharmaceuticals52 → 49 (-3)
Montefiore Medical Center23 → 20 (-3)
University of North Carolina, Chapel Hill23 → 20 (-3)
Milton S. Hershey Medical Center19 → 16 (-3)
Florida State University12 → 9 (-3)
Kailera3 → 0 (-3)
Tubulis GmbH3 → 0 (-3)

A fall here does not mean an organization stopped work. A trial leaves this count when it finishes enrolling, which is the normal end of a successful study, and large centers cycle studies in and out every month.

About this report

Data source. All figures are derived from the public ClinicalTrials.gov registry, queried monthly across 17 condition categories.

Worldwide trials, US sites. Our query is not restricted by country, so the trial counts here cover everything recruiting for these conditions anywhere in the world. We only store site locations that are in the United States. A trial therefore counts toward our totals whether or not you could enroll in it domestically, and 10,834 of 30,933 currently have a US site. Issues 1 through 3 reported the worldwide figure under a US heading without drawing this distinction; the numbers in those issues were correct as worldwide counts, but the label was not. The condition and city pages elsewhere on this site have always filtered to trials with a US site.

A note on the window. This issue compares consecutive months (September → October), the same one-month cadence as Issues 2 through 5. Deltas over a single month are naturally smaller than the two-month window Issue 1 covered, so read the magnitudes here against that shorter window.

What “recruiting” means. A trial is recruiting when ClinicalTrials.gov flags its overall status as RECRUITING. When a trial no longer appears in our monthly fetch, we mark it as “not recruiting”. It may have completed enrollment, been suspended, terminated, or moved to active-not-recruiting status. We don't distinguish between those states in the aggregates above.

What “exited” means. A drug exited recruiting if it had at least one trial flagged RECRUITING in September 2026 and has zero such trials in October 2026. The drug itself isn't gone. Its open trial pipeline is.

Limitations. Our extraction filters out generic terms (placebo, chemotherapy, radiation, saline) and intervention names longer than 60 characters, so very long trial-arm descriptions aren't counted as drugs. Some drugs appear under multiple aliases; we deduplicate where we can.